Ideaya Biosciences Inc (IDYA) Unusual Options Activity Today

Checking IDYA unusual options activity helps you spot when traders are making outsized bets on Ideaya Biosciences Inc before the broader market catches on. Ideaya Biosciences Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor IDYA unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching IDYA unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking IDYA unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and IDYA unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.

The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Catalysts rarely arrive without a footprint, and IDYA unusual options activity is often where that footprint shows up first. Our scanner tracks Ideaya Biosciences Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at IDYA unusual options volume on the call side or chasing put sweeps, Ideaya Biosciences Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.